Literature DB >> 29614677

18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal.

Christopher M Lee1,2, Heidi I L Jacobs1,2,3,4, Marta Marquié5,6, John A Becker1,2, Nicolas V Andrea1,2, David S Jin1,2, Aaron P Schultz2,7, Matthew P Frosch5,6,8,3, Teresa Gómez-Isla5,6,3, Reisa A Sperling5,7,9,3, Keith A Johnson1,2,5,9,3.   

Abstract

BACKGROUND: On target 18F-Flortaucipir (FTP) binding of Alzheimer's disease tau aggregates and off-target binding of melanocytes have been demonstrated with autoradiography.
OBJECTIVE: We aimed to investigate the hypothesis that if binding in choroid plexus (CP) is due to melanocytes, the signal would be elevated in Black/African American (B/AA) compared to White (W) participants. In addition, we examined whether CP signal affects measurements in adjacent regions, and whether correcting for spill-in effects has an influence on associations between hippocampus (HC) FTP and amyloid or cognition.
METHODS: FTP race differences in 147 Harvard Aging Brain Study participants (23 B/AA, 124W) were examined in CP, HC, HC covaried for CP, amygdala, inferior temporal gyrus, entorhinal cortex, and fusiform regions. Associations between CP FTP and other regions-of-interest (ROIs) were probed to assess spill-in effects. A statistical regression approach to attenuate CP spill-in was tested by relating adjusted HC SUVR residuals and unadjusted HC SUVR to race, cognition and amyloid. All analyses were covaried for age, sex, education and amyloid deposition, and Bonferroni-corrected for multiple comparisons.
RESULTS: B/AA individuals had elevated CP and HC SUVR (p < 0.007), whereas other ROI SUVR and HC SUVR covaried for CP SUVR did not show race differences (p > 0.05). CP SUVR was associated with HC SUVR (p < 10-14), but with no other ROI SUVR (p > 0.05). When adjusting HC SUVR for CP SUVR, no race differences in residual HC SUVR were detected, and relationships with amyloid and memory became apparent.
CONCLUSION: Melanocyte FTP binding may account partially for high CP signal. This off-target binding affects mainly HC FTP measurements, which should be interpreted with caution.

Entities:  

Keywords:  Alzheimer’s disease; choroid plexus; melanin; off-target binding; race; tau PET

Mesh:

Substances:

Year:  2018        PMID: 29614677      PMCID: PMC5957532          DOI: 10.3233/JAD-170840

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  35 in total

1.  Tau PET in Alzheimer disease and mild cognitive impairment.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; Jae Hoon Lee; You Jin Kim; Hye Mi Lee; Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

2.  Curly fiber and tangle-like inclusions in the ependyma and choroid plexus--a pathogenetic relationship with the cortical Alzheimer-type changes?

Authors:  J Miklossy; R Kraftsik; O Pillevuit; D Lepori; C Genton; F T Bosman
Journal:  J Neuropathol Exp Neurol       Date:  1998-12       Impact factor: 3.685

3.  Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system.

Authors:  B Fischl; M I Sereno; A M Dale
Journal:  Neuroimage       Date:  1999-02       Impact factor: 6.556

4.  Distinguishing normal and demented elderly with the selective reminding test.

Authors:  D M Masur; P A Fuld; A D Blau; L J Thal; H S Levin; M K Aronson
Journal:  J Clin Exp Neuropsychol       Date:  1989-10       Impact factor: 2.475

5.  Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials.

Authors:  Adam S Fleisher; Abhinay D Joshi; Karen L Sundell; Yun-Fei Chen; Sara Kollack-Walker; Ming Lu; Sherry Chen; Michael D Devous; John Seibyl; Kenneth Marek; Eric R Siemers; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2017-03-30       Impact factor: 21.566

6.  Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.

Authors:  Eric D Hostetler; Abbas M Walji; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Hyking Haley; Marie Holahan; Mona Purcell; Kerry Riffel; Talakad G Lohith; Paul Coleman; Aileen Soriano; Aimie Ogawa; Serena Xu; Xiaoping Zhang; Elizabeth Joshi; Joseph Della Rocca; David Hesk; David J Schenk; Jeffrey L Evelhoch
Journal:  J Nucl Med       Date:  2016-05-26       Impact factor: 10.057

7.  The prevalence of the neuropathological lesions of Alzheimer's disease is independent of race and gender.

Authors:  G Sandberg; W Stewart; J Smialek; J C Troncoso
Journal:  Neurobiol Aging       Date:  2001 Mar-Apr       Impact factor: 4.673

Review 8.  Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Authors:  Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2012-05       Impact factor: 3.685

9.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

10.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.

Authors:  Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad
Journal:  Alzheimers Dement       Date:  2016-02-15       Impact factor: 21.566

View more
  29 in total

1.  The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.

Authors:  Reisa A Sperling; Elizabeth C Mormino; Aaron P Schultz; Rebecca A Betensky; Kathryn V Papp; Rebecca E Amariglio; Bernard J Hanseeuw; Rachel Buckley; Jasmeer Chhatwal; Trey Hedden; Gad A Marshall; Yakeel T Quiroz; Nancy J Donovan; Jonathan Jackson; Jennifer R Gatchel; Jennifer S Rabin; Heidi Jacobs; Hyun-Sik Yang; Michael Properzi; Dylan R Kirn; Dorene M Rentz; Keith A Johnson
Journal:  Ann Neurol       Date:  2019-01-21       Impact factor: 10.422

Review 2.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

3.  Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span.

Authors:  Suzanne L Baker; Theresa M Harrison; Anne Maass; Renaud La Joie; William J Jagust
Journal:  J Nucl Med       Date:  2019-03-15       Impact factor: 10.057

Review 4.  Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.

Authors:  Hiroshi Matsuda; Yoko Shigemoto; Noriko Sato
Journal:  Jpn J Radiol       Date:  2019-09-06       Impact factor: 2.374

5.  In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals.

Authors:  Sandhitsu R Das; Long Xie; Laura E M Wisse; Nicolas Vergnet; Ranjit Ittyerah; Salena Cui; Paul A Yushkevich; David A Wolk
Journal:  Alzheimers Dement       Date:  2019-09-06       Impact factor: 21.566

6.  The presubiculum links incipient amyloid and tau pathology to memory function in older persons.

Authors:  Heidi I L Jacobs; Jean C Augustinack; Aaron P Schultz; Bernard J Hanseeuw; Joseph Locascio; Rebecca E Amariglio; Kathryn V Papp; Dorene M Rentz; Reisa A Sperling; Keith A Johnson
Journal:  Neurology       Date:  2020-04-09       Impact factor: 9.910

Review 7.  Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic.

Authors:  Michael L Alosco; Julia Culhane; Jesse Mez
Journal:  Neurotherapeutics       Date:  2021-04-13       Impact factor: 7.620

8.  Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.

Authors:  Danielle V Mayblyum; J Alex Becker; Heidi I L Jacobs; Rachel F Buckley; Aaron P Schultz; Jorge Sepulcre; Justin S Sanchez; Zoe B Rubinstein; Samantha R Katz; Kirsten A Moody; Patrizia Vannini; Kathryn V Papp; Dorene M Rentz; Julie C Price; Reisa A Sperling; Keith A Johnson; Bernard J Hanseeuw
Journal:  Neurology       Date:  2021-05-05       Impact factor: 9.910

9.  Association of Midlife Depressive Symptoms with Regional Amyloid-β and Tau in the Framingham Heart Study.

Authors:  Mitzi M Gonzales; Jasmeet Samra; Adrienne O'Donnell; R Scott Mackin; Joel Salinas; Mini E Jacob; Claudia L Satizabal; Hugo J Aparicio; Emma G Thibault; Justin S Sanchez; Rebecca Finney; Zoe B Rubinstein; Danielle V Mayblyum; Ron J Killiany; Charlie S Decarli; Keith A Johnson; Alexa S Beiser; Sudha Seshadri
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

10.  Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults.

Authors:  Daniel S Albrecht; Abhay Sagare; Maricarmen Pachicano; Melanie D Sweeney; Arthur Toga; Berislav Zlokovic; Helena Chui; Elizabeth Joe; Lon Schneider; John C Morris; Tammie Benzinger; Judy Pa
Journal:  Brain Behav Immun       Date:  2021-01-22       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.